Oppenheimer Maintains Outperform on TransMedics Gr, Raises Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on TransMedics Group (TMDX) and raises the price target from $92 to $105.
February 27, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on TransMedics Group and raises the price target from $92 to $105.
The increase in price target by a reputable analyst suggests a strong bullish sentiment towards TMDX, likely leading to positive investor perception and potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100